lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
280 rows where filing_period = "third_quarter", filing_year = 2021 and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, income_amount, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2675418 | LUNGREN LOPINA LLC e2c5bbea-923b-4487-819a-2c82c131aea4 | Q3 | LUNGREN LOPINA LLC | 401103314 | AMPAC FINE CHEMICALS | 2021 | third_quarter | PHA | Fair treatment for US based pharmaceutical ingredients | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2021-09-27T16:38:07.957000-04:00 | |
| 2675966 | RED+BLUE STRATEGIES 248c2449-bae5-4452-a830-60ecdd75b586 | 3T | RED+BLUE STRATEGIES | 400693064 | PEW CHARITABLE TRUSTS | 2021 | third_quarter | PHA | PL 117-2 - The American Rescue Plan Act Implementation - Issues related to the increased substance use disorder crisis in America, the need for a more robust pipeline for antibiotics to protect the nation, a more coherent HIT system to ensure robust public data and other related public health issues. S. 963 - Mainstreaming Addiction Treatment Act (The MAT Act) - Supporting access to MAT to help avoid opioid-related deaths in the country. S. 963 - Mainstreaming Addiction Treatment Act (The MAT Act) - Supporting access to MAT to help avoid opioid-related deaths in the country. S. 2076 - The Pioneering Antimicrobial Subscriptions to End Surging Resistance Act ( PASTEUR Act) - Issues related to improving the antibiotic pipeline to address antimicrobial resistance. Issues related to ensuring clear information regarding the safety of supplements. Issues related to dealing with antimicrobial resistance among the US population. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 1 | 2021-10-03T11:20:41.550000-04:00 | |
| 2676066 | AMERICAN COLLEGE OF CLINICAL PHARMACY c75f644f-7937-43e1-a672-d9019562331a | Q3 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2021 | third_quarter | PHA | Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 144981 | 0 | 0 | 2021-10-04T10:02:17.787000-04:00 | |
| 2676594 | VICKI J HICKS df650e9b-fe60-4ac0-8694-40da89e5e04e | Q3 | VICKI J HICKS | 401106146 | A2 STRATEGIES, LLC OBO PHIBRO ANIMAL HEALTH CORPORATION | 2021 | third_quarter | PHA | Animal health issues. | SENATE | 0 | 0 | 2021-10-06T11:03:30.170000-04:00 | ||
| 2676663 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES 94e8a2c0-2e88-4089-90c7-7e2b0dc42679 | Q3 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 26672 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2021 | third_quarter | PHA | Interfaced with the White House, Operation Warp Speed; HHS Secretary and team, and CDC to drive COVID testing & vaccinations across the nation. H.R. 1002 Debarment Enforcement of Bad Actor Registrants Act H.R. 1899 Ensuring Compliance Against Drug Diversion Act | Centers For Disease Control & Prevention (CDC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 370000 | 0 | 0 | 2021-10-06T12:09:49.377000-04:00 | |
| 2676850 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 33a22331-4872-45eb-aa5f-4e16f2516a50 | Q3 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 401103605 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 2021 | third_quarter | PHA | COVID-19 vaccine & therapeutic production, and pandemic protection. Pharmaceutical supply chain and domestic manufacturing | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-07T09:38:56.130000-04:00 | |
| 2676997 | REPUBLIC CONSULTING, LLC 3625bf38-b6f0-40b5-b6b7-00866b8bb143 | Q3 | REPUBLIC CONSULTING, LLC | 401016871 | IQVIA | 2021 | third_quarter | PHA | Monitored Health Data Policy. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-10-07T13:59:53.117000-04:00 | |
| 2677367 | STONINGTON GLOBAL 3b531f7c-1c4b-42b0-9c74-e757ddf53f93 | Q3 | STONINGTON GLOBAL | 401105189 | SORRENTO THERAPEUTICS, INC. | 2021 | third_quarter | PHA | Regulatory approvals and funding for pharmaceutical products and devices | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 150000 | 0 | 0 | 2021-10-08T13:55:06.893000-04:00 | |
| 2677393 | STONINGTON GLOBAL 446c48c7-1ad8-4d76-ab1e-3e7238e5202e | 3T | STONINGTON GLOBAL | 401105189 | NOSTRUM PHARMACEUTICALS LLC | 2021 | third_quarter | PHA | Issues affecting generic pharmaceutical manufacturers | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2021-10-08T14:17:17.110000-04:00 | ||
| 2677485 | INDEPENDENT PHARMACY COOPERATIVE 5c581cfe-d2f7-4842-a6b8-8ba85e4d93fa | Q3 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2021 | third_quarter | PHA | IPC supports S. 1909/H.R. 3554, the Pharmacy DIR Reform to Reduce Senior Drug Costs Act. Support regulations/laws that would eliminate pharmacy DIR. IPC supports Pharmacists as Providers under Medicare Part B. IPC supports Pharmacy and Medically Underserved Areas Enhancement Act, H.R. 2759/S. 1362 IPC supports Pharmacists as Immunizers IPC supports 340B Program and contract pharmacies IPC supports Federal Retail Pharmacy COVID-19 Vaccination Program expansion. IPC supports MCO Medicaid reform and elimination of spread pricing | Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 30000 | 0 | 0 | 2021-10-08T17:13:53.780000-04:00 | |
| 2677611 | PENN AVENUE PARTNERS 3ea2815e-9ec5-48b8-97ca-ee782d9676e9 | Q3 | PENN AVENUE PARTNERS | 400918672 | ALKERMES, INC. | 2021 | third_quarter | PHA | Regulatory and legislative issues impacting Alkermes. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-10T11:57:32.233000-04:00 | |
| 2677664 | PENN AVENUE PARTNERS 4e81ea50-cec0-4e31-8754-937dc7699d4f | Q3 | PENN AVENUE PARTNERS | 400918672 | UNITEDHEALTH GROUP, INC. | 2021 | third_quarter | PHA | Pharmacy benefit related issues. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 90000 | 0 | 0 | 2021-10-10T12:41:48.527000-04:00 | |
| 2677717 | RED+BLUE STRATEGIES 4bb74057-da1d-4629-a972-9f7fcb913240 | Q3 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2021 | third_quarter | PHA | Build Back Better Act - Support of full repeal of the Trump Administration's Rebate Rule. H.R. 3684 - INVEST in America Act - Support for delay of the Trump Administration's Rebate rule PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance. | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2021-10-10T17:45:02.870000-04:00 | |
| 2677742 | RED+BLUE STRATEGIES 8858a006-cb0f-4089-a008-ae3d743d72ce | Q3 | RED+BLUE STRATEGIES | 400693064 | COHERUS BIOSCIENCES | 2021 | third_quarter | PHA | Build Back Better Act - Issues related to supporting the growth of biosimilars in America to provide competition and tools to lower the cost of prescription medications Work to advance policies that support companies that fully manufacture products in America. S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-10-11T09:33:13.227000-04:00 | |
| 2677863 | POLSINELLI PC c56a41ca-ad49-477b-899f-50b09bc7c53e | Q3 | POLSINELLI PC | 314911 | TEVA PHARMACEUTICALS USA, INC. | 2021 | third_quarter | PHA | Issues related to pricing, reimbursement, and manufacturing of pharmaceutical products Review of Administration telehealth policies | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2021-10-11T14:17:55.427000-04:00 | |
| 2678075 | NATIONAL ADVOCACY CENTER OF THE SISTERS OF THE GOOD SHEPHERD 003da944-73d3-413b-b724-0cf05b01ad4f | Q3 | NATIONAL ADVOCACY CENTER OF THE SISTERS OF THE GOOD SHEPHERD | 77993 | CONFERENCE OF PROVINCIALS OF NORTH AMERICA | 2021 | third_quarter | PHA | Advocated to lower the cost of prescription drugs as part of the FY2022 Budget Resolution and in Build Back Better. | Agriculture, Dept of (USDA),Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Interior, Dept of (DOI),Justice, Dept of (DOJ),SENATE,State, Dept of (DOS),Treasury, Dept of,U.S. Agency for International Development (USAID),Vice President of the U.S.,White House Office | 40000 | 0 | 0 | 2021-10-11T16:17:43.907000-04:00 | |
| 2678430 | AMERICAN PHARMACISTS ASSOCIATION c529c99a-2a1a-447d-a4d7-c01659f7809b | Q3 | AMERICAN PHARMACISTS ASSOCIATION | 3071 | AMERICAN PHARMACISTS ASSOCIATION | 2021 | third_quarter | PHA | H.R. 3554/S.1909 The Pharmacy DIR Reform To Reduce Senior Drug Costs Act, to amend title XVIII of the Social Security Act to reform requirements with respect to direct and indirect remuneration under Medicare part D, and for other purposes. H.R. 3662 -- The Patient Access to Urgent-Use Pharmacy Compounding Act of 2021, to amend the Federal Food, Drug, and Cosmetic Act to ensure patients have access to certain urgent-use compounded medications, and for other purposes. H.R. 3682 --To amend title XI of the Social Security Act to provide greater transparency for discounts provided by manufacturers. H.R. 2608 --Ensuring Seniors Access to Local Pharmacies Act of 2021, a bill that establishes several requirements for prescription drug plans under the Medicare prescription drug benefit. | HOUSE OF REPRESENTATIVES,SENATE | 35000 | 0 | 0 | 2021-10-12T12:24:16.420000-04:00 | |
| 2678556 | PANNONE LOPES DEVEREAUX & O'GARA LLC 7aaf670f-2498-4d1d-a5ef-6183f6b789c5 | Q3 | PANNONE LOPES DEVEREAUX & O'GARA LLC | 401105501 | AMGEN | 2021 | third_quarter | PHA | Prescription drug pricing. | 9000 | 0 | 0 | 2021-10-12T13:45:46.987000-04:00 | ||
| 2678885 | MCDERMOTT+ LLC 03f11e99-0518-4f0c-b231-b257d8754b06 | Q3 | MCDERMOTT+ LLC | 401103287 | ALLIANCE FOR RURAL HOSPITAL ACCESS | 2021 | third_quarter | PHA | Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program, including the Closing Loopholes for Orphan Drugs Act (H.R. 853). | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-12T18:01:03.233000-04:00 | |
| 2679215 | ISEMAN & ASSOCIATES LLC 2528ad86-fe3b-4a85-8fde-6c9077a3a12c | Q3 | ISEMAN & ASSOCIATES LLC | 401103582 | TICHENOR VENTURES, LLC | 2021 | third_quarter | PHA | Monitoring biotech legislation; prescription drug prices; COVID- Relief legislation; Infrastructure Legislation; FY22 Appropriations bills | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2021-10-13T12:03:07.827000-04:00 | |
| 2679289 | MLJ STRATEGIES 794f689d-3f48-4c1d-96bf-26ab06c73e60 | Q3 | MLJ STRATEGIES | 401105126 | ANKURA CONSULTING GROUP, LLC ON BEHALF OF ON DEMAND PHARMACEUTICALS | 2021 | third_quarter | PHA | Advocating on issues related to pharmaceutical appropriations | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2021-10-13T13:30:29.443000-04:00 | ||
| 2679296 | MLJ STRATEGIES 4d39bc6f-cc06-4c89-ba6a-5d9530d62251 | Q3 | MLJ STRATEGIES | 401105126 | ANKURA CONSULTING GROUP, LLC ON BEHALF OF THORNE RESEARCH | 2021 | third_quarter | PHA | Advocate on issues related to supplement use in the military | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2021-10-13T13:34:31.737000-04:00 | ||
| 2679653 | CONNECT 4 STRATEGIES, LLC c0855fd6-afe8-476c-8705-3a2b542a6da6 | Q3 | CONNECT 4 STRATEGIES, LLC | 401103720 | OREXO US, INC. | 2021 | third_quarter | PHA | Legislative and regulatory issues pertaining to Orexo Implementation of the SUPPORT act. Access to Digital Therapeutics (S3532) MAT Digital Therapeutics Support Recovery Act. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2021-10-13T19:37:17.113000-04:00 | |
| 2680508 | FOLEY & LARDNER LLP bd48ed63-4c99-466a-8c28-173cface19bd | Q3 | FOLEY & LARDNER LLP | 15042 | BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY) | 2021 | third_quarter | PHA | Market-based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-14T14:37:48.057000-04:00 | |
| 2680625 | FOLEY & LARDNER LLP 875b3d2f-5d28-4a21-9296-c2980e5aa947 | Q3 | FOLEY & LARDNER LLP | 15042 | ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY | 2021 | third_quarter | PHA | FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market. | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2021-10-14T15:30:18.290000-04:00 | |
| 2680748 | BOLD STRATEGIES, LLC 3a60c080-78ae-42e9-b955-4bb454565880 | Q3 | BOLD STRATEGIES, LLC | 401104653 | MORRIS & DICKSON CO., LLC | 2021 | third_quarter | PHA | Prescription drug issues generally. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2021-10-14T17:04:59.657000-04:00 | |
| 2680904 | FOLEY & LARDNER LLP 8374170c-c6e3-42cf-9e22-cc2d7e39cbfa | Q3 | FOLEY & LARDNER LLP | 15042 | FOUNDATION CONSUMER HEALTHCARE LLC | 2021 | third_quarter | PHA | Legislation and regulations affecting marketing and commercialization of prescription and non-prescription drugs | HOUSE OF REPRESENTATIVES,SENATE | 5000 | 0 | 0 | 2021-10-14T21:08:52.990000-04:00 | |
| 2680907 | ACG ADVOCACY 25b8deaf-bdfa-433f-a9a7-8a75b09d6b20 | Q3 | ACG ADVOCACY | 2057 | WALGREEN CO. | 2021 | third_quarter | PHA | Drug Pricing Policy Issues. Data privacy and DIR fee reform. Counterfeiting Issues. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-14T21:10:54.097000-04:00 | |
| 2681020 | TODD STRATEGY GROUP 6c003377-d233-4902-8737-f21fd1db5463 | Q3 | TODD STRATEGY GROUP | 401103321 | ALKERMES, INC. | 2021 | third_quarter | PHA | Prescription drug pricing. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-15T08:06:34.127000-04:00 | |
| 2681059 | TODD STRATEGY GROUP d728036f-f8a7-4953-9aeb-29ab21eacd48 | Q3 | TODD STRATEGY GROUP | 401103321 | ASTRAZENECA PHARMACEUTICALS LP | 2021 | third_quarter | PHA | Drug pricing. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-10-15T09:25:44.177000-04:00 | |
| 2681060 | TODD STRATEGY GROUP c50e6701-37d7-4c2a-ad6d-54b0536f9543 | Q3 | TODD STRATEGY GROUP | 401103321 | BAYER CORPORATION | 2021 | third_quarter | PHA | Drug pricing. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-15T09:28:44.743000-04:00 | |
| 2681073 | TODD STRATEGY GROUP b78f988f-2dba-400f-b0f8-36be09077ccf | Q3 | TODD STRATEGY GROUP | 401103321 | BIOTECHNOLOGY INNOVATION ORGANIZATION | 2021 | third_quarter | PHA | Drug pricing and access. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 60000 | 0 | 0 | 2021-10-15T09:40:48.793000-04:00 | |
| 2681074 | TODD STRATEGY GROUP c39b7c8c-1950-4fa2-ac62-beea8db62ef6 | Q3 | TODD STRATEGY GROUP | 401103321 | CAREDX, INC. | 2021 | third_quarter | PHA | Immunosuppressive drug coverage implementation. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES | 40000 | 0 | 0 | 2021-10-15T09:41:49.363000-04:00 | |
| 2681077 | NELSON MULLINS RILEY & SCARBOROUGH 7b37a819-003d-4a88-bdb9-56f4b4abbb70 | Q3 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | HEMOPHILIA OF GEORGIA | 2021 | third_quarter | PHA | 340B Drug Pricing Program, Medicare, biomedical research, ACA implementation and COVID-19 response and relief legislation | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2021-10-15T09:46:50.440000-04:00 | |
| 2681114 | LINCOLN PARK GROUP L.L.C. dc811b3c-4bfc-4c46-89bb-94e5988fe2bd | Q3 | LINCOLN PARK GROUP L.L.C. | 401104374 | CANADIAN INTERNATIONAL PHARMACY ASSOCIATION | 2021 | third_quarter | PHA | Support for S. 920/H.R. 2181 - A bill to amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals and S. 259/H.R. 832 - Safe and Affordable Drugs from Canada Act; issues related to personal drug importation. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2021-10-15T10:11:01.400000-04:00 | |
| 2681144 | TODD STRATEGY GROUP 6b5c2cb5-84dd-40de-8e48-ae7d88a7b288 | Q3 | TODD STRATEGY GROUP | 401103321 | EMD SERONO INC. | 2021 | third_quarter | PHA | Drug pricing policy. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-15T10:18:07.857000-04:00 | |
| 2681164 | TODD STRATEGY GROUP 46cc416b-ee40-418f-82a2-6f3bb5a5a8c3 | Q3 | TODD STRATEGY GROUP | 401103321 | GENENTECH, INC. | 2021 | third_quarter | PHA | Prescription drug payment reform. Supply chain. Strategic National Stockpile. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-10-15T10:22:12.460000-04:00 | |
| 2681205 | TODD STRATEGY GROUP 72212c13-2eee-43bc-a74b-9c01b66a0058 | Q3 | TODD STRATEGY GROUP | 401103321 | MERCK & CO., INC. | 2021 | third_quarter | PHA | Drug Pricing. 340B Issues. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2021-10-15T10:35:23.847000-04:00 | |
| 2681209 | TODD STRATEGY GROUP 8f8b7488-7287-43e8-a879-b7a9d2287f51 | Q3 | TODD STRATEGY GROUP | 401103321 | NOVARTIS, INC. | 2021 | third_quarter | PHA | Drug Pricing. Supply Chain. 340B Issues. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-15T10:40:25.810000-04:00 | |
| 2681223 | TODD STRATEGY GROUP e37012ae-4da2-47ca-9f01-15f2f0bff617 | Q3 | TODD STRATEGY GROUP | 401103321 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2021 | third_quarter | PHA | Drug Pricing and Access. Pharmaceutical Supply Chain. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-10-15T10:43:29.550000-04:00 | |
| 2681251 | UNIVERSITY OF IOWA e54be645-16c7-4735-89a7-a846cbb561ec | Q3 | UNIVERSITY OF IOWA | 49191 | UNIVERSITY OF IOWA | 2021 | third_quarter | PHA | Support for National Center of Excellence in Advanced and Continuous Pharmaceutical Manufacturing legislation | Agriculture, Dept of (USDA),Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,Natl Oceanic & Atmospheric Administration (NOAA),SENATE | 60000 | 0 | 0 | 2021-10-15T10:46:32.843000-04:00 | |
| 2681473 | BALLARD PARTNERS 95663fe8-3130-4491-87fb-e18632b3c30a | Q3 | BALLARD PARTNERS | 401104288 | THE CRANEWARE GROUP (F.K.A. SENTRY DATA SYSTEMS) | 2021 | third_quarter | PHA | 340B Drug Discount Program. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2021-10-15T12:02:35.457000-04:00 | |
| 2681485 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 169df1f1-0e58-410d-bdb2-bbe86c75c22a | Q3 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 312496 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 2021 | third_quarter | PHA | 340B | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office | 31485 | 0 | 0 | 2021-10-15T12:07:40.287000-04:00 | |
| 2681495 | KOUNTOUPES DENHAM CARR & REID, LLC 3700fff0-d18a-4c7c-9d95-cbf12831bbbf | Q3 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | GLENMARK PHARMACEUTICALS, INC., USA | 2021 | third_quarter | PHA | Issues related to affordability, essential medicine manufacturing and supply chain, and pricing of pharmaceuticals. General issues related to the generic drug industry. Issues related to H.R. 2853, the BLOCKING Act of 2021. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-15T12:10:43.697000-04:00 | |
| 2681599 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION ddfc45b6-83fa-438d-b236-fd6679a625b9 | Q3 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 27478 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 2021 | third_quarter | PHA | S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021; H.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021; H.R. 3656, the Vaccine Access Improvement Act of 2021; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; COVID vaccine distribution; Pharmacist scope of practice, including authorities established by the Public Readiness and Emergency Preparedness (PREP) Act; H.R. 4390, the PROTECT 340B Act of 2021; S. 1574, the Long-Term Care Pharmacy Definition Act of 2021; Provider Relief Fund; Implementation of Pubic Law 113-54, the Drug Quality and Security Act; | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Federal Reserve System,Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Justice, Dept of (DOJ),Occupational Safety & Health Administration (OSHA),SENATE,Small Business Administration (SBA),Treasury, Dept of,White House Office | 420000 | 0 | 0 | 2021-10-15T13:05:07.690000-04:00 | |
| 2681796 | PUBLIC CITIZEN 159a4999-edab-4d0e-8b1c-7d1225b030f9 | Q3 | PUBLIC CITIZEN | 32362 | PUBLIC CITIZEN | 2021 | third_quarter | PHA | HR3778/S 1976 (NOVID Act); Covid-19 Vaccine manufacturing and access and related funding, HR 3 (Lower Drug Costs Now Act, Senate Finance Drug price reform package, Aducanumab, Drug pricing, Insulin affordability for all Act, Medicare Negotiation and Competitive Licensing Act, We PAID Act, S. 1435-Affordable Prescriptions for Patients Act, Vaccine manufacturing and NDAA | Consumer Product Safety Commission (CPSC),Equal Employment Opportunity Commission (EEOC),Federal Accounting Standards Advisory Board (FASAB),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,Natl Telecommunications & Information Administration (NTIA),SENATE,Treasury, Dept of,White House Office | 80000 | 0 | 0 | 2021-10-15T14:38:47.207000-04:00 | |
| 2681843 | BROWN & FORTUNATO, P.C. e5b0bc3a-7857-4f26-8a50-2c58f6b78da2 | Q3 | BROWN & FORTUNATO, P.C. | 401104878 | PROMPTCARE COMPANIES, INC. | 2021 | third_quarter | PHA | Issues related to Medicare home infusion therapy benefit and other health care issues. Issues related to the Medicare DMEPOS competitive bidding program and Medicare coverage and payment for non-invasive ventilators. | Centers For Medicare and Medicaid Services (CMS) | 20000 | 0 | 0 | 2021-10-15T14:46:55.773000-04:00 | |
| 2682354 | AMERICAN VETERINARY MEDICAL ASSOCIATION 9c734d76-dd36-4042-9aaa-efd8ad1447fd | Q3 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 3630 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 2021 | third_quarter | PHA | Prescription Mandate legislation Compounding Guidance (GFI 256) | Agriculture, Dept of (USDA),Education, Dept of,Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 210000 | 0 | 0 | 2021-10-15T21:26:03.973000-04:00 | |
| 2682536 | BLUE CROSS AND BLUE SHIELD ASSOCIATION b19dc5fe-625e-4628-a695-92228b66eaea | Q3 | BLUE CROSS AND BLUE SHIELD ASSOCIATION | 6358 | BLUE CROSS AND BLUE SHIELD ASSOCIATION | 2021 | third_quarter | PHA | COVID-19 Testing; COVID-19 Vaccine Strategy and Treatment; Vaccine Rollout; Rx reform; Prescription drugs; Prescription Drug Reform; H.R. 550 - Immunization Infrastructure Modernization Act of 2021 Sponsor: Rep. Annie Kuster (D-NH-02) H.R. 951 - Maternal Vaccination Act Sponsor: Rep. Terri Sewell (D-AL-07) H.R. 2347 - Strengthening the Vaccines for Children Program Act of 2021 Sponsor: Rep. Kim Schrier (D-WA-08) H.R. 3742 - Vaccine INFO Act Sponsor: Rep. Gus Bilirakis (R-FL-12) H.R. 3 - Lower Drug Costs Now Act Sponsor: Rep. Frank Pallone (D-NJ-06) H.R. 2355 - Opioid Prescription Verification Act of 2021 Sponsor: Rep. Rodney David (R-IL-13) | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,White House Office | 1350000 | 0 | 0 | 2021-10-16T05:14:43.767000-04:00 | |
| 2682555 | MARSHALL & POPP, LLC a3df2660-d18e-4b67-86cf-7312571df5c8 | Q3 | MARSHALL & POPP, LLC | 401105121 | AMGEN USA INC. | 2021 | third_quarter | PHA | Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-10-16T08:51:29.393000-04:00 | |
| 2682558 | MARSHALL & POPP, LLC 3be130e4-ba5b-4e81-bfaa-e63b0107e3c2 | Q3 | MARSHALL & POPP, LLC | 401105121 | BUTTERFLY NETWORK, INC. | 2021 | third_quarter | PHA | Issues related to medical device manufacturing / insurance / technology. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2021-10-16T08:58:29.997000-04:00 | |
| 2682574 | MARSHALL & POPP, LLC f83c1fac-7221-416c-b040-03f86a362f4b | Q3 | MARSHALL & POPP, LLC | 401105121 | GENENTECH, INC. | 2021 | third_quarter | PHA | Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-10-16T09:14:34.210000-04:00 | |
| 2682588 | MARSHALL & POPP, LLC 36379c31-fa0e-408c-b3eb-8918f279216c | Q3 | MARSHALL & POPP, LLC | 401105121 | PFIZER, INC. | 2021 | third_quarter | PHA | Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-10-16T09:25:38.690000-04:00 | |
| 2682594 | MARSHALL & POPP, LLC 91162211-0aa7-411d-b8f0-d88ee7545097 | Q3 | MARSHALL & POPP, LLC | 401105121 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2021 | third_quarter | PHA | Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S. 2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2021-10-16T09:29:39.803000-04:00 | |
| 2682601 | MARSHALL & POPP, LLC 44afd58b-0f40-462b-93c8-71022e394e63 | Q3 | MARSHALL & POPP, LLC | 401105121 | SANOFI U.S. SERVICES, INC. | 2021 | third_quarter | PHA | Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-10-16T09:32:41.543000-04:00 | |
| 2682815 | GOVERNMENT COUNSEL, LLC 546c6f2e-c1d5-49de-8c1d-f7a6e0b042f5 | Q3 | GOVERNMENT COUNSEL, LLC | 401105070 | HEALTHCARE DISTRIBUTION ALLIANCE | 2021 | third_quarter | PHA | H.R. 768-Block, Report, And Suspend Suspicious Shipments Act of 2021; Policies related to ARCOS data and suspicious order record requirements; Implementation of Public Law 113-54 (DSCSA). | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-10-16T13:49:04.577000-04:00 | |
| 2683160 | CAPITOL COUNSEL LLC 504e615d-c9be-44d7-b953-aa6a7638a7d3 | Q3 | CAPITOL COUNSEL LLC | 313715 | EMD SERONO, INC. | 2021 | third_quarter | PHA | Monitoring and engaging on health policy proposals coming before the House of Representatives and the Administration pertaining to the availability and pricing of prescription drugs. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-16T19:53:30.727000-04:00 | |
| 2683263 | FORBES-TATE 59786460-4ea0-4226-83f8-7eb256239856 | Q3 | FORBES-TATE | 400976792 | INDEPENDENT PHARMACY COOPERATIVE | 2021 | third_quarter | PHA | Issues related to pharmacy regulation, the MAC Transparency Act, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-10-17T11:49:08.777000-04:00 | |
| 2683909 | MEHLMAN CONSULTING, INC. d207093d-26aa-471c-a1bc-1d48d99ec587 | Q3 | MEHLMAN CONSULTING, INC. | 284950 | AMNEAL | 2021 | third_quarter | PHA | Monitoring legislative and regulatory efforts related to domestic supply chains of generic drugs. Pandemic Preparedness. The Build Back Better Act, a bill to provide for reconciliation pursuant to title II of the Concurrent Resolution on the Budget for Fiscal Year 2022, S. Con. Res. 14. | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 60000 | 0 | 0 | 2021-10-18T09:37:51.060000-04:00 | |
| 2683938 | MEHLMAN CONSULTING, INC. 29c1dd4d-8c36-4442-8a43-0a8e22a15a94 | Q3 | MEHLMAN CONSULTING, INC. | 284950 | ASCENSION HEALTH ALLIANCE | 2021 | third_quarter | PHA | 340B Drug Pricing Program. Financial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19. The Build Back Better Act, A bill to provide for reconciliation pursuant to title II of the Concurrent Resolution on the Budget for Fiscal Year 2022, S. Con. Res. 14. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-18T09:44:58.323000-04:00 | |
| 2683947 | MEHLMAN CONSULTING, INC. 8ea90ca2-9432-4d22-b6b6-a6ca4bc75bdd | Q3 | MEHLMAN CONSULTING, INC. | 284950 | BLUE SHIELD OF CALIFORNIA | 2021 | third_quarter | PHA | Prescription drug pricing. The Build Back Better Act, A bill to provide for reconciliation pursuant to title II of the Concurrent Resolution on the Budget for Fiscal Year 2022, S. Con. Res. 14. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-18T09:48:00.907000-04:00 | |
| 2684159 | MEHLMAN CONSULTING, INC. 4094bd0e-dbac-41bb-be1e-29eea35ef496 | Q3 | MEHLMAN CONSULTING, INC. | 284950 | THE CAMPAIGN FOR SUSTAINABLE RX PRICING | 2021 | third_quarter | PHA | S.1391 - Fair Accountability and Innovative Research Drug Pricing Act. Prescription drug pricing issues. Patent abuse issues. Ensuring Innovation Act and the Advancing Education on Biosimilars Act of 2021. Drug-price Transparency for Competition (DTC) Act. The Build Back Better Act, A bill to provide for reconciliation pursuant to title II of the Concurrent Resolution on the Budget for Fiscal Year 2022, S. Con. Res. 14. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 110000 | 0 | 0 | 2021-10-18T10:33:53.350000-04:00 | |
| 2684179 | AARP 5c3e7275-f994-4ffa-b0ca-d05d21a626d3 | Q3 | AARP | 1694 | AARP | 2021 | third_quarter | PHA | H.R. 5376 Build Back Better Act. No bill number. Discussed prescription drugs prices and costs and Medicare. H.R. 4356, Agriculture, Rural Development Appropriations Act, FY 2022. S. 1428, the Preserve Access to Affordable Generics and Biosimilars Act. S. 1287, the REFUND Act. | Administration for Children & Families (ACF),Agriculture, Dept of (USDA),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Consumer Financial Protection Bureau (CFPB),Corporation for Natl & Community Service,Defense, Dept of (DOD),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Internal Revenue Service (IRS),Labor, Dept of (DOL),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),Office of Personnel Management (OPM),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),Transportation, Dept of (DOT),Treasury, Dept of,Veterans Affairs, Dept of (VA),White House Office | 2980000 | 0 | 0 | 2021-10-18T10:37:55.780000-04:00 | |
| 2684230 | MEHLMAN CONSULTING, INC. 830b5b4e-ae0d-44f8-a7cb-bdf2f6fc8d95 | Q3 | MEHLMAN CONSULTING, INC. | 284950 | VIZIENT INC | 2021 | third_quarter | PHA | Issues related to Unapproved Drug Initiative. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 60000 | 0 | 0 | 2021-10-18T10:50:09.973000-04:00 | |
| 2684279 | WATKINS & EAGER PLLC 98120117-54e1-4674-9044-931ce97af690 | Q3 | WATKINS & EAGER PLLC | 401104403 | ZYNERBA PHARMACEUTICALS, INC. | 2021 | third_quarter | PHA | Providing services on behalf of Zynerba to the pharmaceutical industry | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 45000 | 0 | 0 | 2021-10-18T10:59:21.243000-04:00 | |
| 2684283 | WAXMAN STRATEGIES aa7d8769-bde2-45a3-ad63-04dfb09367d4 | Q3 | WAXMAN STRATEGIES | 401103693 | 340B HEALTH | 2021 | third_quarter | PHA | Issues affecting the 340B drug pricing program; Appropriations for 340B program. | HOUSE OF REPRESENTATIVES,SENATE | 45000 | 0 | 0 | 2021-10-18T10:59:21.750000-04:00 | |
| 2684659 | BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC 89c7f8ed-ccb8-495e-ace3-869d045caf65 | Q3 | BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC | 401104621 | BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC | 2021 | third_quarter | PHA | HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances | HOUSE OF REPRESENTATIVES,SENATE,White House Office | 100000 | 0 | 0 | 2021-10-18T12:03:00.890000-04:00 | |
| 2684820 | FORBES-TATE 644c826f-f452-4042-8235-dde0167ed442 | Q3 | FORBES-TATE | 400976792 | CALIFORNIA LIFE SCIENCES ASSOCIATION | 2021 | third_quarter | PHA | Issues related to the life sciences industry; Issues related to drug pricing and international reference pricing. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-18T12:26:40.670000-04:00 | |
| 2685174 | CORNERSTONE GOVERNMENT AFFAIRS, INC. 09824afa-ff19-49f7-81f1-3f27f93e467b | Q3 | CORNERSTONE GOVERNMENT AFFAIRS, INC. | 75557 | VYRIPHARM ENTERPRISES, INC. | 2021 | third_quarter | PHA | Policies and regulations associated with testing, tracing and tracking of cannabinoids. | HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE | 30000 | 0 | 0 | 2021-10-18T14:01:21.610000-04:00 | |
| 2685301 | FORBES-TATE 9adcf7df-0924-43ac-82bd-f530fc32d657 | Q3 | FORBES-TATE | 400976792 | MERCK | 2021 | third_quarter | PHA | Issues related to prescription drug pricing, vaccines, animal health, and maternal health. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-18T14:27:50.743000-04:00 | |
| 2685646 | TARPLIN, DOWNS & YOUNG, LLC 025d29dd-3015-4af5-b399-5e9fb27be353 | Q3 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | ASTRAZENECA | 2021 | third_quarter | PHA | Drug coverage & reimbursement vaccination no specific bills, Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation, transparency, 340B, pay for delay | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2021-10-18T14:50:48.073000-04:00 | |
| 2685824 | FORBES-TATE f457df06-815e-4441-9e06-fc422b1667d0 | Q3 | FORBES-TATE | 400976792 | PHRMA | 2021 | third_quarter | PHA | Issues pertaining to prescription drug pricing. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2021-10-18T15:09:26.693000-04:00 | |
| 2685995 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION b227d517-6264-4c06-980d-db34be734d54 | Q3 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2021 | third_quarter | PHA | OTC switch process -- no bill number Cures 2.0 -- no bill number S.1435/HR 2873 - Affordable Prescriptions for Patients Act of 2021 H.R.4405 - Small Business FDA User Fee Adjustment Act of 2021 | Commerce, Dept of (DOC),Food & Drug Administration (FDA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of | 133000 | 0 | 0 | 2021-10-18T15:26:05.173000-04:00 | |
| 2686418 | SUSAN B ANTHONY LIST aeae88ed-97c3-4d77-9625-a2d2fed5ecb5 | Q3 | SUSAN B ANTHONY LIST | 400935704 | SUSAN B ANTHONY LIST | 2021 | third_quarter | PHA | H.R. 554, S. 78 Support and Value Moms and Babies Act; Chemical abortion | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 230000 | 0 | 0 | 2021-10-18T16:13:33.260000-04:00 | |
| 2686512 | TARPLIN, DOWNS & YOUNG, LLC b0c49244-04c1-43e8-8e8f-355008fd822d | Q3 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | BIOTECHNOLOGY INDUSTRY ORGANIZATION | 2021 | third_quarter | PHA | H.R. 1319, American Rescue Plan of 2021 implementation no specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, patent settlements, break through therapies, Innovation, transparency no specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, Innovation | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 80000 | 0 | 0 | 2021-10-18T16:27:57.893000-04:00 | |
| 2686744 | WINNING STRATEGIES WASHINGTON 60ebd16e-cbe7-4ede-aa95-c10789192e5c | Q3 | WINNING STRATEGIES WASHINGTON | 50796 | KALEO | 2021 | third_quarter | PHA | Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2021-10-18T17:06:53.627000-04:00 | |
| 2686776 | HANCE SCARBOROUGH b26d9696-4e6e-477c-abe0-6a6fc1e5cb6d | Q3 | HANCE SCARBOROUGH | 17443 | BOEHRINGER INGELHEIM USA CORPORATION | 2021 | third_quarter | PHA | Provide ongoing animal health policy monitoring, assessment, and research support. Telemedicine/telehealth legislation. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2021-10-18T17:18:00.967000-04:00 | |
| 2686801 | HANCE SCARBOROUGH 4a01986b-27c3-4cd5-a31a-e60a04a92216 | Q3 | HANCE SCARBOROUGH | 17443 | ALLIANCE FOR PHARMACY COMPOUNDING | 2021 | third_quarter | PHA | Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2022 Appropriations HR3662, the Patient Access to Urgent Use Compounded Medication Act | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-10-18T17:25:06.193000-04:00 | |
| 2686810 | BROWNSTEIN HYATT FARBER SCHRECK, LLP b9014dc0-e00a-4d03-9e69-61f96b4ce868 | Q3 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | AIPHARMA GLOBAL HOLDINGS LIMITED | 2021 | third_quarter | PHA | Issues related to the pharmaceutical supply chain | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office | 80000 | 0 | 0 | 2021-10-18T17:28:08.097000-04:00 | |
| 2686841 | HANCE SCARBOROUGH c24ef9e9-c2cf-4fec-b079-ee00d306acef | Q3 | HANCE SCARBOROUGH | 17443 | PHRMA | 2021 | third_quarter | PHA | Patent reform regarding pharmaceutical research & products. | SENATE | 30000 | 0 | 0 | 2021-10-18T17:37:14.677000-04:00 | |
| 2686846 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 24e32f99-8678-4843-8be7-9bd1fd91a211 | Q3 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 401104060 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 2021 | third_quarter | PHA | General education around pharmaceuticals related to Parkinson's disease | Centers For Medicare and Medicaid Services (CMS),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 52751 | 0 | 0 | 2021-10-18T17:37:15.593000-04:00 | |
| 2686874 | KOUNTOUPES DENHAM CARR & REID, LLC c677cea8-e9ce-4202-a7ba-17eb77b024b7 | Q3 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) | 2021 | third_quarter | PHA | Issues related to proposals that would address drug shortages and national stockpile issues, including H.R. 2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to COVID-19 vaccine distribution. Issues related to the implementation of H.R. 1319, the American Rescue Plan. Issues related to pharmacy provider status. Issues related to oncology medicines in H.R. 5067, the Preserving Patient Access to Home Infusion Act. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 60000 | 0 | 0 | 2021-10-18T17:50:21.420000-04:00 | |
| 2687250 | KNIGHT CAPITOL CONSULTANTS 6c204db0-76ba-4575-8365-38b582889bab | Q3 | KNIGHT CAPITOL CONSULTANTS | 40036301 | EQUASHIELD, LLC | 2021 | third_quarter | PHA | Provisions affecting vial reuse being discussed in connection with drug pricing legislation (H.R. 5376, Build Back Better Act). | Centers For Disease Control & Prevention (CDC),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2021-10-18T21:18:53.907000-04:00 | |
| 2687294 | KNIGHT CAPITOL CONSULTANTS bd357551-47b2-4c50-96d2-919b0c79a27c | Q3 | KNIGHT CAPITOL CONSULTANTS | 40036301 | REGENXBIO | 2021 | third_quarter | PHA | Possible legislation which may affect Food and Drug Administration review of biologic products (no specific bill) | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-10-18T21:43:03.370000-04:00 | |
| 2687303 | WEST FRONT STRATEGIES LLC 9dcb06e3-7553-46f0-aacc-0be30e7009d3 | Q3 | WEST FRONT STRATEGIES LLC | 401103493 | WALGREEN CO. | 2021 | third_quarter | PHA | Issues related to COVID-19 vaccination programs; issues related to pharmacy, pharmacist provider status, and Medicare reimbursement. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-18T21:55:06.483000-04:00 | |
| 2687340 | FLYNN & ASSOCIATES, INC. 6245f9ed-c797-4d92-ba0c-bd7b662fb8b2 | Q3 | FLYNN & ASSOCIATES, INC. | 15020 | PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION | 2021 | third_quarter | PHA | H.R. 3 - Price controls for prescription drugs. Importation of drugs from other countries. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-10-18T22:32:14.263000-04:00 | |
| 2687813 | VAN SCOYOC ASSOCIATES 316fa875-1e94-410b-ab2b-6c2341de1a40 | Q3 | VAN SCOYOC ASSOCIATES | 39837 | ZEBRA TECHNOLOGIES CORP. | 2021 | third_quarter | PHA | Temperature monitoring technology for COVID-19 vaccines, Domestic and International distribution related issues Temperature monitoring technology, generally | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2021-10-19T05:32:00.937000-04:00 | |
| 2687882 | BROYDRICK & ASSOCIATES f77ff540-32d3-4b2b-bf38-6a930fc75da9 | Q3 | BROYDRICK & ASSOCIATES | 7268 | EXELA PHARMA SCIENCES | 2021 | third_quarter | PHA | Drug shortages and FDA approval, USTR acceptance. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2021-10-19T06:35:15.933000-04:00 | |
| 2687911 | BROYDRICK & ASSOCIATES 8abcfded-18ed-48e9-82b9-4114531a7b38 | Q3 | BROYDRICK & ASSOCIATES | 7268 | TONIX PHARMACEUTICALS | 2021 | third_quarter | PHA | Funding new drug for PTSD and COVID 19. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2021-10-19T06:49:26.830000-04:00 | |
| 2688016 | MASSACHUSETTS MEDICAL SOCIETY 68af04a9-4366-400c-a0bb-72c5d5e29dc7 | Q3 | MASSACHUSETTS MEDICAL SOCIETY | 23975 | MASSACHUSETTS MEDICAL SOCIETY | 2021 | third_quarter | PHA | Issues related to prescription drug prices - no specific bill Issues related to vaccines - no specific bill | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Treasury, Dept of,Veterans Affairs, Dept of (VA),White House Office | 50000 | 0 | 0 | 2021-10-19T08:34:59.760000-04:00 | |
| 2688248 | TARPLIN, DOWNS & YOUNG, LLC 1e0e8337-b35b-4214-b18b-08b9df1778a0 | Q3 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) | 2021 | third_quarter | PHA | Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271) Issues related to ARCOS data and suspicious order record requirements and reporting (HR 768) Importation of Prescription Drugs (HR 832, HR 2181, S 259, S 920, Public Law 108-173) Implementation of Public Law 113-54 (DSCSA) | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2021-10-19T09:17:45.540000-04:00 | |
| 2688451 | ELI LILLY AND COMPANY 9ae26008-a4a1-4795-8f34-2645e9954c25 | Q3 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2021 | third_quarter | PHA | Hospital discounts; 340B program | Commerce, Dept of (DOC),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR) | 1320000 | 0 | 0 | 2021-10-19T09:41:40.167000-04:00 | |
| 2688550 | CRISPR THERAPEUTICS, INC. 80a30d2a-42af-444f-afb5-73e4f624442a | Q3 | CRISPR THERAPEUTICS, INC. | 401105184 | CRISPR THERAPEUTICS, INC. | 2021 | third_quarter | PHA | Coverage & reimbursement for Cell and Gene Therapies | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-10-19T09:51:07.977000-04:00 | |
| 2688769 | M.J. SIMON & COMPANY, LLC f345b90a-2cd0-48fc-9d86-6278b01e676f | Q3 | M.J. SIMON & COMPANY, LLC | 40026223 | NOBELPHARMA AMERICA | 2021 | third_quarter | PHA | FDA inspections | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2021-10-19T10:09:52.907000-04:00 | ||
| 2688890 | TWENTY-FIRST CENTURY GROUP, INC. 8b3deb0e-803e-4166-81a7-c80287090924 | Q3 | TWENTY-FIRST CENTURY GROUP, INC. | 38687 | CARDINAL HEALTH, INC. | 2021 | third_quarter | PHA | Issues related to the distribution and sale of pharmaceutical and medical products and services; medical and public health preparedness; COVID-19pandemic response; and the healthcare supply chain. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2021-10-19T10:19:17.687000-04:00 | |
| 2688893 | BUCHANAN INGERSOLL & ROONEY PC 2f4f19d3-0618-4c28-b306-fbaa5d725cc5 | Q3 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | GENERIC ANIMAL DRUG ALLIANCE | 2021 | third_quarter | PHA | Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2021-10-19T10:19:18.140000-04:00 | |
| 2689171 | UNITED FOOD & COMMERCIAL WORKERS INTERNATIONAL UNION 2b552729-dd3b-4d3a-abd4-668d34fc751a | Q3 | UNITED FOOD & COMMERCIAL WORKERS INTERNATIONAL UNION | 39121 | UNITED FOOD & COMMERCIAL WORKERS INTERNATIONAL UNION | 2021 | third_quarter | PHA | Met with Senate staff regarding prescription drug reform. | HOUSE OF REPRESENTATIVES,SENATE | 200000 | 0 | 0 | 2021-10-19T10:45:09.630000-04:00 | |
| 2689452 | KOUNTOUPES DENHAM CARR & REID, LLC 86af380f-7bc7-4de6-a56a-2ea7b94f9b58 | Q3 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CVS HEALTH | 2021 | third_quarter | PHA | General education about the pharmacy benefit manager/pharmacy and insurance industry. Issues related to drug pricing. Issues related to the drug supply chain. Issues related to the implementation of H.R. 133, Consolidated Appropriations Act for Fiscal Year 2021. Issues related to the implementation of H.R. 1319, The American Rescue Plan, including provisions related to vaccine distribution. Issues related to the Fiscal Year 2022 budget reconciliation process focusing on drug pricing. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-10-19T11:17:06.287000-04:00 | |
| 2689453 | FORBES-TATE 0c7986fe-e86d-4773-8b62-20f525a28681 | Q3 | FORBES-TATE | 400976792 | VERDE TECHNOLOGIES | 2021 | third_quarter | PHA | Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2021-10-19T11:17:06.720000-04:00 | |
| 2689595 | SUMMIT PUBLIC AFFAIRS 58cfb562-72f6-4181-927e-0a8f892e24da | Q3 | SUMMIT PUBLIC AFFAIRS | 401105467 | VANDA PHARMACEUTICALS INC. | 2021 | third_quarter | PHA | Issues affecting the pharmaceutical industry, including the prescription drug approval process. 21st Century Cures Act 2.0 (proposed legislation). | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2021-10-19T11:31:44.320000-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);